Super-enhancer-driven ITGB2-AS1 promotes ovarian cancer progression by binding to IQGAP1
Authors:
Open Access
- 4 June 2026
- journal article
- Published by Elsevier in Translational Oncology
- Vol. 70, 102844
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82072864)
This publication has 51 references indexed in Scilit:
- Multi‐Omics Analysis Reveals That the MAZ / HDGF Regulatory Axis Drives High‐Grade Serous Ovarian Cancer Progression by Modulating Glycolysis and M2 Macrophage PolarizationIUBMB Life, 2025
- Ovarian CancerJAMA, 2025
- Small and long non-coding RNAs: Past, present, and futureCell, 2024
- LncRNA SNHG1 facilitates colorectal cancer cells metastasis by recruiting HNRNPD protein to stabilize SERPINA3 mRNACancer Letters, 2024
- LncRNA‐CCAT5‐mediated crosstalk between Wnt/β‐Catenin and STAT3 signaling suggests novel therapeutic approaches for metastatic gastric cancer with high Wnt activityCancer Communications, 2023
- Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum ResistanceJAMA Oncology, 2023
- Oncogenic super-enhancers in cancer: mechanisms and therapeutic targetsCancer and Metastasis Reviews, 2023
- A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in CancerCancer Cell, 2020
- Targeting tumor microenvironment in ovarian cancer: Premise and promiseBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2020
- Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity GenesCell, 2013